Design, synthesis, and cytoprotective effect of 2-aminothiazole analogues as potent poly(ADP-Ribose) polymerase-1 inhibitors

Journal of Medicinal Chemistry

Volumn 52, Issue 3, 2009, Pages 718-725

  Zhang, Wen Ting ^a   Ruan, Jin Lan ^a,c   Wu, Peng Fei ^b   Jiang, Feng Chao ^a,c   Zhang, Li Na ^a   Fang, Wei ^a   Chen, Xiang Long ^b   Wang, Yue ^a   Cao, Bao Shuai ^a   Chen, Gang Ying ^a   Zhu, Yi Jing ^a   Gu, Jun ^b   Chen, Jian Guo ^b,c  

^a Department of Medicinal Chemistry ^*  (China)

^b HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^c Hubei Key Laboratory of Natural Medicinal Chemistry and Resource Evaluation   (China)

Author keywords

[No Author keywords available]

Indexed keywords

2 AMINOTHIAZOLE DERIVATIVE; 3 AMINOBENZAMIDE; ETHYL 4 OXO 4 (4 PHENYLTHIAZOL 2 YLAMINO)BUTANOATE; HYDROGEN PEROXIDE; N (4 PHENYLTHIAZOL 2 YL)CINNAMAMIDE; N [(1H INDOL 3 YL)METHYLENE] 4 (2,4 DIETHOXYPHENYL)THIAZOL 2 AMINE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; UNCLASSIFIED DRUG; ADPRT PROTEIN, RAT; ENZYME INHIBITOR; NEUROPROTECTIVE AGENT; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; THIAZOLE DERIVATIVE;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL DAMAGE; CELL PROTECTION; CELL STRAIN; CELL VIABILITY; COLORIMETRY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG DESIGN; DRUG POTENCY; DRUG SYNTHESIS; ENZYME ACTIVITY; ENZYME INHIBITION; FLOW CYTOMETRY; IC 50; NEUROLOGIC DISEASE; NEUROPROTECTION; NONHUMAN; PHARMACOPHORE; PHYSICAL CHEMISTRY; THREE DIMENSIONAL IMAGING; ANIMAL; CELL SURVIVAL; DRUG ANTAGONISM; DRUG EFFECT; RAT; SYNTHESIS;

ANIMALS; APOPTOSIS; CELL SURVIVAL; CYTOPROTECTION; DRUG DESIGN; ENZYME INHIBITORS; HYDROGEN PEROXIDE; NEUROPROTECTIVE AGENTS; PC12 CELLS; POLY(ADP-RIBOSE) POLYMERASES; RATS; THIAZOLES;

EID: 61449098663     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm800902t     Document Type: Article

References (32)

1. Nguewa, P. A.; Fuertes, M. A.; Valladares, B.; Alonso, C.; Perez, J. M. Poly(ADP-ribose) polymerases: Homology, structural domains and functions. Novel therapeutical applications. Prog. Biophys. Mol. Biol. 2005, 88, 143-172.
2. Ame, J. C.; Spenlehauer, C.; Murcia, G. The PARP superfamily. Bioessays 2004, 26, 882-893.
3. Tentori, L.; Portarena, I.; Graziani, G. Potential clinical applications of poly(ADP-ribose) polymerase (PARP) inhibitors. Pharmacol. Res. 2002, 45, 73-85.
4. Ha, H. C.; Snyder, S. H. Poly(ADP-ribose) polymerase is a mediator of necrotic cell death by depletion. Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13978-13982.
5. Oliver, F. J.; Murcia, C. N.; Nacci, C.; Decker, P.; Andriantsitohaina, R.; Muller, S.; Rubia, G.; Stoclet, J. C.; Murcia, G. Resistance to endotoxic shock as a consequence of defective NF-KB activation in poly(ADP-ribose) polymerase-1 deficient mice. EMBO J. 1999, 18, 4446-4454.
6. Mandir, A. S.; Poitras, M. F.; Berliner, A. R.; Herring, W. J.; Guastella, D. B.; Feldman, A.; Poirier, G. G.; Wang, Z. Q.; Dawson, T. M.; Dawson, V. L. NMDA but not non-NMDA excitotoxicity is mediated by poly(ADP-ribose) polymerase. Neuroscience 2000, 20, 8005-8011.
7. Pieper, A. A.; Wallws, T.; Wei, G.; Clements, E. E.; Verma, A.; Snyder, S. H.; Zweier, J. L. Myocardial postischemic injury is reduced by poly(ADP-ribose) polymerase-1 gene disruption. Mol. Med. 2000, 6, 271-282.
8. Yu, S. W.; Wang, H.; Poitras, C. C.; Bowers, W. J.; Federoff, H. J.; Poirier, G. G.; Dawson, T. M.; Dawson, V. L. Mediation of poly(ADP - ribose) polymerase-1-dependent cell death by apoptosis-inducing factor. Science 2002, 297, 259-263.
9. Kauppinen, T. M.; Swanson, R. A. The role of poly(ADP-ribose) polymerase-1 in CNS disease. Neuroscience. 2007, 145, 1267-1272.
10. Ferraris, D.; Ficco, R. P.; Dain, D.; Ginski, M.; Lautar, S.; Wisdom, K. L.; Liang, S.; Lin, Q.; Lu, M. X. C.; Morgan, L.; Thomas, B.; Williams, L. R.; Zhang, J; Zhou, Y.; Kalish, V. J. Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 4: Biological evaluation of imidazobenzodiazepines as potent PARP-1 inhibitors for treatment of ischemic injuries. Bioorg. Med. Chem. 2003, 11, 3695-3707.
11. Iwashita, A.; Hattori, K.; Yamamoto, H.; Ishida, J.; Kido, Y.; Kamijo, K.; Murano, k.; Miyake, H.; Kinoshita, T.; Warizaya, M.; Ohkubo, M.; Matsuoka, N.; Mutoh, S. Discovery of quinazolinone and quinoxaline derivatives as potent and selective poly(ADP-ribose) polymerase-1/2 inhibitors. FEBS Lett. 2005, 579, 1389-1393.
12. Steinhagen, H.; Gerisch, M.; Mittendorf, J.; Schlemmer, K. H.; Albrecht, B. Subtituted uracil derivatives as potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. 2002, 12, 3187-3190.
13. Jagtap, P. G.; Southan, G. J.; Baloglu, E.; Ram, S.; Mabley, J. G.; Marton, A.; Salzman, A.; Szabo, C. The discovery and sythesis of novel adenosine substituted 2, 3-dihydro-1 H-isoindol-1-ones: Potent inhibitors of poly(ADP-ribose) polymerase-1 (PARP-1). Bioorg. Med. Chem. Lett. 2004, 14, 81-85.
14. Loh, V. M.; Cockcroft, X. L.; Dillon, K. J.; Dixon, L.; Drzewiecki, J.; Eversley, P. J.; Gomez, S.; Hoare, J.; Kerrigan, F.; Matthews, L. T. W.; Menear, K. A.; martin, N. M. B.; Newton, R. F.; Paul, J.; Smith, G. C. M.; Vile, J.; whittle, A. J. Phthalazinones. Part 1: The design and synthesis of a novel series of potent inhibitors of poly(ADP - ribose) polymerase. Bioorg. Med. Chem. Lett. 2005, 15, 2235-2238.
15. Ferraris, D.; Ko, Y. S.; Phhuski, T.; Ficco, R. P.; Serdyuk, L.; Alemu, C.; Bradford, C.; Chiou, T.; Hoover, R.; Huang, S.; Lautar, S.; Liang, S.; lin, Q.; Lu, M. X. C.; Mooney, M.; Morgan, L.; Qian, Y.; Tran, S.; Williams, L. R.; Wu, Y. Q.; Zhang, J.; Zou, Y.; Kalish, V. Design and synthesis of poly ADP-ribose polymerase-1 inhibitors. 2. Biological evaluation of aza-5[H]-phenanthridin-6-ones as potent, aqueous-soluble compounds for the treatment of ischemic injuries. J. Med. Chem. 2003, 46, 3138-3151.
16. Ferraris, D.; Ficco, R. P.; Pahutski, T.; Lautar, S.; Huang, S.; Zhang, J.; Kalish, V. Design and synthesis of poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors. Part 3: In vitro evalution of 1,3,4,5-tetrahydro - benzo[c][1,6] - and [c][1,7]-naphthyridin-6-ones. Bioorg. Med. Chem. Lett. 2003, 13, 2513-2518.
17. Kurogi, Y.; Guner, O. F. Pharmacophore modeling and three - dimensional database searching for drug design using catalyst. Curr. Med. Chem. 2001, 8, 1035-1055.
18. Debnath, A. K. Pharmacophore mapping of a series of 2,4-diamino - 5-deazapteridine inhibitors of Mycobacterium avium comples dihydrofolate reductase. J. Med. Chem. 2002, 45, 41-53.
19. Kurogi, Y.; Miyata, K.; Okamura, T.; Hashimoto, K.; Tsusumi, K.; Nasu, M.; Moriyasu, M. Discovery of novel mesangial cell proliferation inhibitors using a three-dimensional database searching method. J. Med. Chem. 2001, 44, 2304-2307.
20. Kaminski, J. J.; Rane, D. F.; Snow, M. E.; Weber, L.; Rothofsky, M. L.; Anderson, S. D.; Lin, S. L. Identification of novel farnesyl protein transferase inhibitors using three-dimensional database searching methods. J. Med. Chem. 1997, 40, 4103-4112.
21. Zhang, W. T.; Yan, H.; Jiang, F. C. Construction of pharmacophore model of PARP-1 inhibitor. Yao Xue Xue Bao. 2007, 42, 279-285; Chinese.
22. + binding to poly(ADP-ribose) polymerase as derived from crystal structures and homology modeling. Biochemistry 1998, 37, 3893-3900.
23. Costantino, G.; Macchiarulo, A.; Camaioni, E.; Pellicciari, R. Modeling of poly(ADP-ribose) polymerase (PARP) inhibitors. Docking of ligands and quantitative structure-activity relationship analysis. J. Med. Chem. 2001, 44, 3786-3794.
24. Geronikaki, A.; Dearden, J. C.; Filimonov, D.; Galaeva, I.; Garibova, T. L.; Gloriozova, T.; Krajneva, V.; Lagunin, A.; Macaev, F. Z.; Molodavkin, G.; Poroikov, V. V.; Pogrebnoi, S. I.; Shepeli, F.; Voronina, T. A.; Tsitlakidou, M.; Vlad, L. Design of new congnition enhancers: From computer prediction to synthesis and biological evalution. J. Med. Chem. 2004, 47, 2870-2876.
25. Schneider, C. S.; Mierau, J. Dopamine autoreceptor agonist: Resolution and pharmacological activity of 2,6-diaminotetrahydrobenzothiazole and an aminothiazole analog of apomorphine. J. Med. Chem. 1987, 30, 494-498.
26. Kin, K. M.; Kim, K. H.; Kang, T. C.; Kim, W. Y.; Lee, M.; Jung, H. J.; Hwang, I. K.; Ko, S. B.; Koh, J. Y.; Won, M. H.; Oh, E.; Shin, I. Design and biological evaluation of novel antioxidants containing N-t-butyl -N-hydroxylaminophenyl moieties. Bioorg. Med. Chem. Lett. 2003, 13, 2273-3375.
27. Zhu, X.; Yu, Q. S.; Cutler, R. G.; Culmsee, C. W.; Holloway, H. W.; Lahiri, D. K.; Mattson, M. P.; Greig, N. H. Novel p53 inactivators with neuroprotective action: Syntheses and pharmacological evaluation of 2-imino-2,3,4,5,6,7-hexahydrobenzothiazole and 2-imino-2,3,4,5,6,7 - hexahydrobenzoxazole derivatives. J. Med. Chem. 2002, 45, 5090-5097.
28. King, L. C.; Miller, F. M. The reaction of diazoketones with thioamide derivatives. J. Am. Chem. Soc. 1949, 71, 367-368.
29. King, L. C.; Hlavacek, R. J. The reaction of ketones with iodine and thiourea. J. Am. Chem. Soc. 1950, 72, 3722-3725.
30. Lo, E. N.; Prince, B. H.; Wei, M.; Panahian, N. Inhibition of poly(ADP - ribose) polymerase: Reduction of ischemic injury and attenuation of N-methyl-D-aspartate-induced neurotransmitter dysregulation. Stroke. 1998, 29, 830-836.
31. 2+ signaling in astrocytes in an in vitro ischemic model. Neurobiol. Dis. 2004, 24, 9585-9597.
32. Vermes, I.; Haanen, C.; Nakken, H. S.; Reutelingsperger, C. A novel assay for apoptosis flow cytometric detection of phosphatidylserine expression on early apoptotic cells using fluorescein iabelled annexin V. J. Immunol. Methods 1995, 184, 39-51. JM800902T